- Aptamer Group
- 30 May 2025 10:26:09
Source: Sharecast
Aptamer stated that under the new agreement, it will develop a novel panel of Optimer binders targeting an additional biological pathway associated with body odour formation, potentially providing Unilever with a second strategy to prevent the formation of body malodour.
The AIM-listed group said the agreement was structured on a fee-for-service basis, with Aptamer receiving an undisclosed six-figure sum for the development work. On-person performance trials were anticipated to take place before the end of 2025.
Chief executive Arron Tolley said: "I am excited by the additional project we are undertaking with Unilever. This project expands our partnership with Unilever in the odour control space. The excellent results produced by our team in the first project have resulted in a deepening partnership with Unilever, expanding on the applicability of our Optimer binders.
"The first project is now moving toward on-person trials, and this deal positions us well to create multiple, licensable assets with a global powerhouse in the consumer health market. This second programme reflects the confidence Unilever has in the Optimer platform and the significant value we can unlock by expanding our offering into novel, large-scale applications like personal care."
As of 1025 BST, Aptamer shares were up 11.76% at 0.38p.
Reporting by Iain Gilbert at Sharecast.com